Generic Injectables Market Size & Share | Global Trends 2021, 28

report image

Generic Injectables Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Large Molecule Injectables and Small Molecule Injectables), Container Type (Vials, Premix, Prefilled Syringes, Ampoules, and Others), Application (Oncology, Infectious Diseases, Cardiology, Diabetes, Immunology, and Others), and Route of Administration (Intravenous, Intramuscular, Subcutaneous, and Others), and Geography

Publication Month: Mar 2022 | Report Code: TIPRE00004765 | No. of Pages: 217 | Category: Pharmaceuticals | Status: Published

The generic injectables market is projected to reach US$ 150.65 billion by 2028 from US$ 74.74 billion in 2021; it is expected to register a CAGR of 10.5% from 2021 to 2028.

Generic injectables are the bioequivalents of their branded counterparts and are not protected by patents. They are safe and effective as the innovator drugs since they have similar active ingredients, dosages, strength, qualities, form, etc.

The report offers insights and in-depth analysis of the generic injectables market, emphasizing various parameters such as market trends, technological advancements, and market dynamics; it also provides the competitive landscape analysis of leading market players and the impact of the COVID-19 pandemic on the market across all major regions. The COVID-19 pandemic has disrupted the socioeconomic conditions of various countries across the world. As per the recent WHO statistics, the US is the world's worst-affected country due to the pandemic with the highest number of cases. The high number of COVID cases has negatively impacted the economy of the US, and consequently that of North America. There has been a decline in overall business activities and growth of various industries operating in the region.

Strategic Insights

Report Coverage - Generic Injectables Market
Report CoverageDetails
Market Size Value inUS$ 74.74 billion in 2021
Market Size Value byUS$ 150.65 billion by 2028
Growth rateCAGR of 10.5% from 2021 to 2028
Forecast Period2021- 2028
Base Year2021
No. of Pages217
No. of Tables110
No. of Charts & Figures81
Historical data availableYes
Segments coveredType, Container Type, Application, and Route of Administration, and Geography
Regional scopeNorth America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country scopeUS, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina
Report coverageRevenue forecast, company ranking, competitive landscape, growth factors, and trends
Free Sample Copy Available

However, there was an unusual demand for Remdesivir, an antiviral medicine used to treat patients, when the outbreak was at its peak. Thus, manufacturers in the generic injectables market are now prepared for the future as they focus on keeping adequate stock for keeping supply chain operations unaffected dur to any type of vulnerabilities. Gilead Sciences and other big pharma companies, for example, have reduced the prices of their generic versions of remdesivir considerably. Companies are utilizing government programs and financing schemes offered by the BFSI industries to streamline their operations. In May 2020, the US government entered into an agreement, worth US$ 812 million, with a group of American generic medicine manufacturers, with the goal of bolstering the country's drug supply amid the global COVID-19 pandemic.

Furthermore, the pandemic strained pharmaceutical industries globally, interrupting and delaying supply of various critical drugs. Many market players came to rescue with immediate actions. For instance, in January 2021, Civica Rx teamed up with the brand-new Phlow Corp. in an effort to support drug manufacturing in the US and supply critical medications to hospitals fighting the pandemic. Civica invested US$ 124.5 million in the construction of a sterile injectable manufacturing facility in Petersburg, Virginia, which rose to prominence last year owing to a large government contract to produce COVID-19-related drugs.

Based on region, the generic injectables market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. 

Lucrative Regions for Generic Injectables Market

Lucrative Regions for Generic Injectables Market

Get more information on this report :

Market Insights
High Demand for Affordable Drugs Drives Generic Injectables Market

Innovator drugs are expensive owing to high investments made in the research & development of molecules; these drugs are specifically unaffordable for a large share of the population in developing countries. However, generic drugs are affordable and provide greater access to healthcare. As published by the Association for Accessible Medicines (AAM), the average primary copay (the amount set by the insurance plans) of a generic drug is US$ 6.06 and US$ 40.30 for branded drugs. This fact indicates the falling prices of generic medicines by at least ~7%. According to the American Association of Retired Person (AARP), branded drug prices continue to increase at a pace that is 100-times greater than inflation. Moreover, as mentioned by the USFDA, 9/10 prescriptions filled in the US are for generic drugs. Additionally, the generic drug’s average manufacturer prices (AMP) are ~39% lower than the branded drug’s AMP. For instance, as published by Association for Accessible Medicines (AAM), 93% of generic prescriptions are filled for US$ 20 or less. The facts mentioned above boost the demand and availability of generic injectables, thus driving the entry of more players into the generic injectables market.

Further, low prices of generic injectables contribute to greater and effective chronic illness treatments. As per the World Health Organization (WHO), ~422 million people worldwide were diabetic in 2021. Generic injectables such as insulin injections offer immediate solutions for such ailments, alongside ensuring affordable treatments in developing countries.

Product Type-Based Insights

Based on product type, the generic injectables market is segmented into large molecule injectables and small molecule injectables. In 2021, the large molecule injectables segment accounted for a greater market share. The market position of this segment is credited to a surge in the adoption of biologics in the healthcare sector, and the progress of monoclonal antibody and antibody-drug conjugates (ADCs) into the drug development.

Generic Injectables Market, by Product Type – 2020 and 2028

Generic Injectables Market, by Product Type – 2020 and 2028

Get more information on this report :

Container Type-Based Insights

Based on container type, the generic injectables market is segmented into vials, premix, prefilled syringes, ampoules, and others. The vials segment is likely to dominate the market in 2021.

Application-Based Insights

The generic injectables market, based on application, has been categorized into oncology, infectious diseases, cardiology, diabetes, immunology, and others. The oncology segment is likely to hold the largest share of the market in 2021. An increase in cancer incidences and rise in the launch of drugs is anticipated drives the growth of the oncology market segment.

Route of Administration-Based Insights

Based on the route of administration, the generic injectables market has been categorized into intravenous, intramuscular, subcutaneous, and others. The intravenous segment held the largest market share in 2021.

The generic injectables market players adopt organic strategies such as product launch and expansion to expand their footprint and product portfolio worldwide.

By Geography

  • North America

    • US
    • Canada
    • Mexico
  • Europe

    • France
    • Germany
    • Italy
    • UK
    • Spain
    • Rest of Europe
  • Asia Pacific (APAC)

    • China
    • India
    • South Korea
    • Japan
    • Australia
    • Rest of APAC
  • Middle East & Africa (MEA)

    • South Africa
    • Saudi Arabia
    • UAE
    • Rest of MEA
  • South and Central America (SCAM)

    • Brazil
    • Argentina
    • Rest of SCAM

Company Profiles

  • Astrazeneca
  • Baxter International, Inc.
  • Biocon
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline Plc
  • Hikma Pharmaceuticals
  • Johnson & Johnson Services, Inc.
  • Lupin, Ltd.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Pfizer, Inc                                                                              

Frequently Asked Questions

Generic Injectables are safe and effective innovator bio-equivalent drugs of their branded counterparts which are not protected by drug patents. They have a similar ingredient, dosage, strength, quality, form, etc.
High demand for affordable drugs is one of the most significant factors responsible for the overall market growth.
Based on product type, large molecule injectables took the forefront leaders in the worldwide market by accounting largest share in 2020 and is expected to continue to do so till the forecast period.
The oncology segment dominated the global generic injectables market and accounted for the largest revenue of 21.62 Bn in 2021.
Astrazeneca, Baxter International, Inc., Biocon, Fresenius SE & Co., KGaA, GlaxoSmithKline Plc, Hikma Pharmaceuticals, Johnson & Johnson Services, Inc., Lupin, Ltd., Merck & Co., Inc., Mylan N.V., Pfizer, Inc. are among the leading companies operating in the global generic injectables market
Global generic injectables market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. In North America, the U.S. is the largest market for generic injectables market. The US is estimated to hold the largest share in the generic injectables market during the forecast period. The presence of top players and favorable regulations related to product approvals coupled with commercializing new products are the contributing factors for the regional growth. Additionally, the increasing number of technological advancements is the key factor responsible for the Asia-Pacific regional growth for generic injectables accounting fastest growth of the region during the coming years.

The List of Companies - Generic Injectables Market

  1. Astrazeneca
  2. Baxter International, Inc.
  3. Biocon
  4. Fresenius SE & Co. KGaA
  5. GlaxoSmithKline Plc
  6. Hikma Pharmaceuticals
  7. Johnson & Johnson Services, Inc.
  8. Lupin, Ltd.
  9. Merck & Co., Inc.
  10. Mylan N.V.
  11. Pfizer, Inc.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the generic injectables market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global generic injectables market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market

Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
  • $3000
  • $4550
  • $6550
  • $8550

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount